Oct 20, 2022 09:02 PM (GMT+8) · EqualOcean
Kactus Biosystems (Chinese: 恺佧生物) announced that it had completed a Series B financing round of nearly CNY 200 million. New Alliance Capital led this financing round, followed by Shanghai Lingang LAN WAN Private Fund, GF Capital and a famous multinational life science industry group. Founded in March 2018, Kactus Biosystems is a research-driven, high-tech company focusing on antibody drug discovery and cell gene therapy. SAMS, the complete R&D and production platform for high-activity proteases, provides functional target proteins based on structural design and GMP-controlled protease raw materials for cell and gene therapy and mRNA vaccine.